Compare Stocks: KURA, VCYT, LEGN, and VKTX

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
KURA Kura Oncology	$9.83 -5.5%	$11.39	$7.36 ▼ $13.90	$924.75M	0.47	1.76 million shs	2.71 million shs
LEGN Legend Biotech	$17.88 +0.4%	$19.76	$16.24 ▼ $37.50	$3.45B	0.57	2.24 million shs	2.46 million shs
VCYT Veracyte	$43.11 -2.1%	$43.61	$29.45 ▼ $60.91	$3.54B	1.95	1.56 million shs	760,402 shs
VKTX Viking Therapeutics	$26.65 -6.0%	$32.64	$25.77 ▼ $43.15	$3.57B	0.66	9.31 million shs	5.70 million shs

The Best Nuclear Energy Stocks to Buy

Nuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
KURA Kura Oncology	-1.89%	-2.07%	-8.69%	-7.47%	+5.58%
LEGN Legend Biotech	-4.40%	-5.17%	-4.51%	-30.66%	-43.85%
VCYT Veracyte	-2.68%	-7.66%	+7.71%	-22.25%	+26.49%
VKTX Viking Therapeutics	-0.60%	-3.21%	-11.38%	-25.36%	-15.55%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
KURA Kura Oncology	$9.83 -5.5%	$11.39	$7.36 ▼ $13.90	$924.75M	0.47	1.76 million shs	2.71 million shs
LEGN Legend Biotech	$17.88 +0.4%	$19.76	$16.24 ▼ $37.50	$3.45B	0.57	2.24 million shs	2.46 million shs
VCYT Veracyte	$43.11 -2.1%	$43.61	$29.45 ▼ $60.91	$3.54B	1.95	1.56 million shs	760,402 shs
VKTX Viking Therapeutics	$26.65 -6.0%	$32.64	$25.77 ▼ $43.15	$3.57B	0.66	9.31 million shs	5.70 million shs

The Best Nuclear Energy Stocks to Buy

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
KURA Kura Oncology	-1.89%	-2.07%	-8.69%	-7.47%	+5.58%
LEGN Legend Biotech	-4.40%	-5.17%	-4.51%	-30.66%	-43.85%
VCYT Veracyte	-2.68%	-7.66%	+7.71%	-22.25%	+26.49%
VKTX Viking Therapeutics	-0.60%	-3.21%	-11.38%	-25.36%	-15.55%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
KURA Kura Oncology	2.77	Moderate Buy	$25.69	161.32% Upside
LEGN Legend Biotech	2.53	Moderate Buy	$55.07	208.01% Upside
VCYT Veracyte	2.64	Moderate Buy	$55.78	29.38% Upside
VKTX Viking Therapeutics	2.75	Moderate Buy	$99.44	273.15% Upside

Current Analyst Ratings Breakdown

Latest KURA, VCYT, LEGN, and VKTX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
10/13/2026	LEGN Legend Biotech	Barclays Subscribe to MarketBeat All Access to unlock brokerage rankings	Lower Price Target	Overweight	$74.00 ➝ $68.00
10/9/2026	LEGN Legend Biotech	JPMorgan Chase & Co. Subscribe to MarketBeat All Access to unlock brokerage rankings	Lower Price Target	Neutral	$35.00 ➝ $33.00
10/8/2026	LEGN Legend Biotech	Royal Bank Of Canada Subscribe to MarketBeat All Access to unlock brokerage rankings	Lower Price Target	Outperform	$58.00 ➝ $56.00
10/7/2026	VKTX Viking Therapeutics	Truist Financial Subscribe to MarketBeat All Access to unlock brokerage rankings	Lower Price Target	Buy	$87.00 ➝ $85.00
10/5/2026	KURA Kura Oncology	UBS Group Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Buy
10/2/2026	LEGN Legend Biotech	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Upgrade	Sell (E+) ➝ Sell (D-)
10/2/2026	VCYT Veracyte	Zacks Research Subscribe to MarketBeat All Access to unlock brokerage rankings	Downgrade	Strong-Buy ➝ Hold
10/1/2026	KURA Kura Oncology	JPMorgan Chase & Co. Subscribe to MarketBeat All Access to unlock brokerage rankings	Initiated Coverage	Overweight	$30.00
9/28/2026	LEGN Legend Biotech	UBS Group Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Buy	$65.00
9/28/2026	LEGN Legend Biotech	HC Wainwright Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Buy	$65.00
9/24/2026	VCYT Veracyte	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Downgrade	Hold (C+) ➝ Hold (C)

(Data available from 10/13/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
KURA Kura Oncology	$67.48M	12.96	N/A	N/A	$2.00 per share	4.92
LEGN Legend Biotech	$1.03B	3.37	N/A	N/A	$5.43 per share	3.29
VCYT Veracyte	$517.15M	6.70	$1.46 per share	29.55	$16.57 per share	2.60
VKTX Viking Therapeutics	N/A	N/A	N/A	N/A	$5.65 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
KURA Kura Oncology	-$278.67M	-$3.37	N/A	N/A	N/A	-384.30%	-207.18%	-45.17%	11/3/2026 (Estimated)
LEGN Legend Biotech	-$296.80M	-$0.25	N/A	15.28	N/A	-7.21%	-8.71%	-5.40%	11/11/2026 (Estimated)
VCYT Veracyte	$66.35M	$1.41	28.96	27.99	N/A	20.37%	9.26%	8.61%	11/3/2026 (Estimated)
VKTX Viking Therapeutics	-$359.64M	-$4.66	N/A	N/A	N/A	N/A	-94.56%	-82.75%	10/28/2026 (Estimated)

Latest KURA, VCYT, LEGN, and VKTX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
11/3/2026	Q3 2026	KURA Kura Oncology	-$0.8144	N/A	N/A	N/A	$23.81 million	N/A
11/3/2026	Q3 2026	VCYT Veracyte	$0.4111	N/A	N/A	N/A	$147.16 million	N/A
10/28/2026	Q3 2026	VKTX Viking Therapeutics	-$1.07	N/A	N/A	N/A	N/A	N/A
8/12/2026	Q2 2026	KURA Kura Oncology	-$0.8773	-$0.77	+$0.1073	-$0.77	$20.16 million	$20.87 million
8/11/2026	Q2 2026	LEGN Legend Biotech	$0.07	$0.09	+$0.02	$0.18	$355.96 million	$387.50 million
7/30/2026	Q2 2026	VCYT Veracyte	$0.4103	$0.54	+$0.1297	$0.31	$144.59 million	$150.32 million
7/29/2026	Q2 2026	VKTX Viking Therapeutics	-$1.21	-$1.10	+$0.11	-$1.10	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
KURA Kura Oncology	N/A	N/A	N/A	N/A	N/A
LEGN Legend Biotech	N/A	N/A	N/A	N/A	N/A
VCYT Veracyte	N/A	N/A	N/A	N/A	N/A
VKTX Viking Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
KURA Kura Oncology	0.12	4.73	4.71
LEGN Legend Biotech	N/A	3.04	2.94
VCYT Veracyte	N/A	9.16	8.80
VKTX Viking Therapeutics	N/A	4.72	4.72

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
KURA Kura Oncology	N/A
LEGN Legend Biotech	70.89%
VCYT Veracyte	N/A
VKTX Viking Therapeutics	76.03%

Insider Ownership

Company	Insider Ownership
KURA Kura Oncology	7.60%
LEGN Legend Biotech	0.02%
VCYT Veracyte	1.60%
VKTX Viking Therapeutics	5.30%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
KURA Kura Oncology	260	88.96 million	82.20 million	Optionable
LEGN Legend Biotech	2,965	193.77 million	193.73 million	Optionable
VCYT Veracyte	755	80.39 million	79.11 million	Optionable
VKTX Viking Therapeutics	65	125.99 million	119.31 million	Optionable

KURA, VCYT, LEGN, and VKTX Headlines

Recent News About These Companies

3 Absurdly Cheap Stocks to Buy Before the End of 2026

28 minutes ago | fool.com

Viking Therapeutics (NASDAQ:VKTX) Stock Price Breaks Below Fifty Day Moving Average - Should You Sell?

October 13 at 2:59 AM | marketbeat.com

Novo Down 11% in a Month: How Should Investors Approach the Stock Now?

October 12 at 1:25 PM | zacks.com

Oppenheimer Thinks Viking Therapeutics Stock Can Soar to $120. Here's the Math Behind the Ultra-Bullish Call.

October 12 at 7:22 AM | fool.com

Viking Therapeutics' Oral Obesity Drug Advances to Phase 3 Testing. Is Now the Time to Buy This Biotech Stock?

October 10 at 12:15 PM | fool.com

Viking Therapeutics, Inc. (VKTX) Exceeds Market Returns: Some Facts to Consider

October 9, 2026 | finance.yahoo.com

Viking Therapeutics, Inc. (VKTX) Exceeds Market Returns: Some Facts to Consider

October 9, 2026 | zacks.com

Viking Therapeutics, Inc. (VKTX) Dips More Than Broader Market: What You Should Know

October 8, 2026 | finance.yahoo.com

Viking Therapeutics, Inc. (VKTX) Dips More Than Broader Market: What You Should Know

October 8, 2026 | zacks.com

Analyst Predicts 316% Upside for Viking Therapeutics Stock Despite 30%+ Loss in Last 3 Months

October 8, 2026 | tikr.comT

VKTX Advances Obesity Program With New Oral Maintenance Study

October 7, 2026 | zacks.com

Viking Therapeutics stock fell 3.07 percent as oral trial starts

October 7, 2026 | ad-hoc-news.deA

Viking Therapeutics Launches Phase 2 Oral VK2735 Maintenance Study

October 6, 2026 | rttnews.com

Viking Therapeutics Initiates Trial of VK2735 Maintenance Dosing Regimens in Obesity

October 6, 2026 | finance.yahoo.com

Viking Therapeutics Announces Initiation of VK2735 Oral Maintenance Dosing Clinical Trial in Patients with Obesity

October 6, 2026 | finance.yahoo.com

VKTX Down 16% in a Month: Time to Invest or Exit the Stock?

October 6, 2026 | finance.yahoo.com

VKTX Down 16% in a Month: Time to Invest or Exit the Stock?

October 6, 2026 | zacks.com

Viking Therapeutics Announces Initiation of VK2735 Oral Maintenance Dosing Clinical Trial in Patients with Obesity

October 6, 2026 | prnewswire.com

Viking Therapeutics Inc (Derivatives) Price Today in India

October 6, 2026 | goodreturns.inG

Here Are My Top 4 Stocks to Buy in October

October 5, 2026 | fool.com

Viking Therapeutics (NASDAQ:VKTX) Stock Rating Cut to "Strong Sell" at Wall Street Zen

October 4, 2026 | americanbankingnews.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

KURA, VCYT, LEGN, and VKTX Company Descriptions

Kura Oncology NASDAQ:KURA

$9.83 -0.57 (-5.48%)

Closing price 04:00 PM Eastern

Extended Trading

$9.90 +0.07 (+0.70%)

As of 07:57 PM Eastern

Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors. It has a clinical collaboration with Novartis Pharma AG to evaluate the combination of tipifarnib and alpelisib in patients with head and neck squamous cell carcinoma whose tumors have HRAS overexpression and/or PIK3CA mutation and/or amplification. The company was founded in 2014 and is headquartered in San Diego, California.

Legend Biotech NASDAQ:LEGN

$17.88 +0.08 (+0.45%)

Closing price 04:00 PM Eastern

Extended Trading

$17.94 +0.06 (+0.33%)

As of 07:57 PM Eastern

Legend Biotech Corporation, a clinical-stage biopharmaceutical company, through its subsidiaries, engages in the discovery, development, manufacturing, and commercialization of novel cell therapies for oncology and other indications in the United States, China, and internationally. Its lead product candidate, LCAR- B38M, is a chimeric antigen receptor for the treatment of multiple myeloma (MM). The company also has a portfolio of earlier-stage autologous CAR-T product candidates targeting various cancers, including Non-Hodgkins Lymphoma, acute lymphoblastic leukemia, gastric cancer, esophageal cancer, pancreatic cancer, colorectal cancer, hepatocellular carcinoma, small cell lung cancer, and non-small cell lung cancer. It has collaboration and license agreement with Janssen Biotech, Inc. for the development and commercialization of ciltacabtagene autoleucel. The company was founded in 2014 and is based in Somerset, New Jersey. Legend Biotech Corporation is a subsidiary of Genscript Biotech Corporation.

Veracyte NASDAQ:VCYT

$43.11 -0.91 (-2.07%)

Closing price 04:00 PM Eastern

Extended Trading

$43.58 +0.47 (+1.09%)

As of 07:59 PM Eastern

Veracyte, Inc. engages in the research, development and commercialization of diagnostic products. The firm's portfolio includes Afirma, Percepta, and Envisia. It intends to treat thyroid cancer, improve lung cancer screening, and clarify the diagnosis of idiopathic pulmonary fibrosis. The company was founded by Bonnie H. Anderson and Y. Douglas Dolginow on August 15, 2006 and is headquartered in South San Francisco, CA.

Viking Therapeutics NASDAQ:VKTX

$26.65 -1.69 (-5.96%)

Closing price 04:00 PM Eastern

Extended Trading

$26.74 +0.09 (+0.33%)

As of 07:57 PM Eastern

Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD. It also develops VK5211, an orally available non-steroidal selective androgen receptor modulator that is in Phase II clinical trials for the treatment of patients recovering from non-elective hip fracture surgery; VK0612, an orally available Phase IIb-ready drug candidate for type 2 diabetes; VK2735, a novel dual agonist of the glucagon-like peptide, which is in Phase 1 SAD/MAD clinical trial, and VK0214, an orally available tissue and receptor-subtype selective agonist of the TRß for X-linked adrenoleukodystrophy. The company was incorporated in 2012 and is headquartered in San Diego, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest KURA, VCYT, LEGN, and VKTX Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest KURA, VCYT, LEGN, and VKTX Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

KURA, VCYT, LEGN, and VKTX Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

KURA, VCYT, LEGN, and VKTX Company Descriptions

Kura Oncology NASDAQ:KURA

Legend Biotech NASDAQ:LEGN

Veracyte NASDAQ:VCYT

Viking Therapeutics NASDAQ:VKTX

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest KURA, VCYT, LEGN, and VKTX Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest KURA, VCYT, LEGN, and VKTX Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

KURA, VCYT, LEGN, and VKTX Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

KURA, VCYT, LEGN, and VKTX Company Descriptions

Kura Oncology NASDAQ:KURA

Legend Biotech NASDAQ:LEGN

Veracyte NASDAQ:VCYT

Viking Therapeutics NASDAQ:VKTX

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools